Literature DB >> 6300248

Production of rabbit antibody specific for amino-terminal residues of cholecystokinin octapeptide (CCK-8) by selective suppression of cross-reactive antibody response.

E Hashimura, F Shimizu, T Nishino, K Imagawa, K Tateishi, T Hamaoka.   

Abstract

Antibody specific for the amino-terminal region of cholecystokinin octapeptide (CCK-8) was generated in a highly reproducible way in New Zealand white rabbits by a novel immunization procedure which involves immunization with CCK-8 peptide conjugate coupled with keyhole limpet hemocyanin (KLH) and inhibiting cross-reacting antibody formation by treatment of the animals with a potent tolerogenic conjugate of beta-alanyl-tetragastrin and a copolymer of D-glutamic acid and D-lysine (D-GL). The antisera thus produced specifically react with an amino-terminal region of CCK-8 but not with the non-sulfate form of CCK-8, nor with the carboxy-terminal region which shares a cross-reactive determinant among gastrin and cholecystokinin-related peptides (caerulein, CCK-4, CCK-8, CCK-33 and CCK-39). The antisera produced by this method allowed us to measure specifically CCK in extracts from tissue such as duodenum containing gastrin and CCK at comparable levels.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6300248     DOI: 10.1016/0022-1759(82)90097-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  17 in total

1.  Glucagon-like peptide-1: a potent regulator of food intake in humans.

Authors:  J P Gutzwiller; B Göke; J Drewe; P Hildebrand; S Ketterer; D Handschin; R Winterhalder; D Conen; C Beglinger
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

2.  Effect of a cholecystokinin receptor antagonist (loxiglumide) on gallbladder contractile function in guinea pigs.

Authors:  K Tsubo; M Arai; H Omachi; K Mitamura
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

3.  Effect of methionine-enkephalin analog (FK 33-824) on plasma motilin.

Authors:  K Sekiya; A Funakoshi; I Nakano; H Nawata; K Kato; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1986-08

4.  Plasma gastrin and cholecystokinin response after pylorus-preserving pancreatoduodenectomy with Billroth-I type of reconstruction.

Authors:  A Tangoku; M Nishikawa; A Adachi; T Suzuki
Journal:  Ann Surg       Date:  1991-07       Impact factor: 12.969

5.  Effects of tetraprenylacetone on pancreatic exocrine secretion and acute pancreatitis in two experimental models in rats.

Authors:  I Tachibana; N Watanabe; H Shirohara; T Akiyama; S Nanano; M Otsuki
Journal:  Int J Pancreatol       Date:  1995-04

6.  Dystrophic axons in the nucleus gracilis of the normal rat containing cholecystokinin-like immunoreactivity. Light- and electron-microscopic observations.

Authors:  T Matsuda; M Maeda; Y Morishima; S Hashimoto; K Tateishi; T Hamaoka; H Mizuta; H Takagi
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

7.  Effects of short-term administration of the CCK receptor antagonist, KSG-504, on regeneration of pancreatic acinar cells in acute pancreatitis in rats.

Authors:  Y Okumura; H Inoue; Y Fujiyama; T Bamba
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

8.  Effect of synthetic trypsin inhibitor on plasma immunoreactive cholecystokinin in rats.

Authors:  S Kanayama; S Himeno; Y Yamasaki; Y Shinomura; T Kitani; S Tarui
Journal:  Gastroenterol Jpn       Date:  1987-04

9.  Direct, concentration-dependent inhibition by taurocholate of pancreatic exocrine secretion and CCK release in conscious rats.

Authors:  H Tomita; K Miyasaka; M Matsumoto; A Funakoshi
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

10.  Gallbladder emptying, plasma levels of estradiol and progesterone, and cholecystokinin secretion in liver cirrhosis.

Authors:  M Pompili; G L Rapaccini; E Caturelli; D Curró; P Montuschi; M D'Amato; A Aliotta; A Grattagliano; A Cedrone; M Anti
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.